Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Dx Firm Pacific Edge Achieves CLIA Registration to Offer Bladder Cancer Test in US

NEW YORK (GenomeWeb News) – New Zealand cancer diagnostics company Pacific Edge said today its US Laboratory has achieved registration under the CLIA regulatory process, setting the stage for it to offer its bladder cancer test in the US.

CLIA registration means that Pacific Edge's laboratory in Hershey, Penn., will be able to operate and process urine samples from patients in the US for its laboratory-developed test called Cxbladder. The non-invasive, urine-based test uses molecular signatures to identify the presence of bladder cancer tumors.

In addition to the US, Cxbladder is available in Australia and New Zealand, and the firm anticipates making the test commercially available in Spain soon. Pacific Edge has licensing deals with Oryzon in Spain and Healthscope in Australia for the test.

According to Pacific Edge CEO Jackie Walker, CLIA registration marks the transition of the test to full commercialization mode. The firm has the core of its sales and marketing team in the US in place and is working with urologists on incorporating Cxbladder into their practices. During the coming months, additional sales and marketing personnel will be added, the company said.

Based in Dunedin, New Zealand, Pacific Edge develops diagnostic and prognostic technologies directed at cancer detection and monitoring.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.